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Abstract 
 
Background: 
 Physicians are based on the results of RCTs. It is important the reporting of these 
results to be completed and accurated. Uptoday the quality of RCTs in this disease 
have never been evaluated. 
 
Methods: We searched PubMed Database for assess in the reporting quality of 
randomized-controlled trials of Human Papilloma Virus (HPV) vaccines in cervical 
cancer prevention , based on CONSORT  statement. Quality of reporting was assessed 
using a 24-item questionnaire based on the revised CONSORT checklist. Given that 
all selected Randomized Controlled Trials (n=136) were published after 2006, the 
reporting  quality was evaluated overall, and for pre -CONSORT version 2010 (2006-
2009) - and post-CONSORT version 2010 (2010-1015) periods. 
Results: 
136 eligible trials were identified through literature research strategy.  The 
comparison of pre -CONSORT version 2010 (2006-2009) - and post-CONSORT 
version 2010 (2010-1015) periods revealed a significant improvement (p < 0.05). 
These items were endpoints, sample size, statistical methods, participant flow, patient 
recruitment periods, intention-to-treat analysis, estimation of effects, ancillary 
analyses, adverse events and overall evidence. 
Conclusion: Reporting quality of Randomized- controlled trials of Human 
Papillomavirus (HPV) vaccines in cervical cancer prevention it was improved across 
all items after issuing of CONSORT version 2010 statement implementation. 
Endorsement of the CONSORT statement may optimize the reporting quality and 
enhance the validity of research. 
 
 
Background 
Cervical cancer is the third most common cancer in women and the fourth most 
common cause of death worldwide. Infection with certain types of human 
papillomavirus (HPV) is necessary to develop cervical cancer. This has led to an 
increase in effectiveness of screening for cervical cancer using Pap smears and the 
development of primary prevention through the use of prophylactic vaccines against 
HPV. 
The prophylactic vaccine stimulates the development of the humoral immune 
response, which occurs after contact with the “virus-like particles” (VLPs), which are 
non-infectious structures and simulate a natural HPV infection. The two oncogenic 
types included in both vaccines are HPV 16 and 18, responsible for at least 70% of 
the cases of cervical cancer worldwide. In the case of the quadrivalent vaccine, it also 
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included two non-oncogenic types of HPV, responsible for approximately 90% of 
cases of anogenital condylomata acuminata. 
Safety and tolerability of both vaccines have been evaluated extensively with similar 
profiles in the vaccinated and control groups, irrespective of age or ethnicity. Studies 
about safety assessment indicated that local and systemic injection-related symptoms 
were generally mild. Serious adverse effects (AE) that are considered to be vaccine 
related are rare and similar to other vaccine types. Studies indicate that the most 
common AE is injection-related local reaction, such as pain, swelling and erythema 
with a rate of 95% of light to moderate intensity. Regarding systemic symptoms, 
fever, nausea, vomiting, dizziness, myalgia and diarrhea were reported.Severe AE, 
such as severe headache with hypertension, gastroenteritis and bronchospasm, were 
described in 0.5%.15 There are more data available of AE associated with the 
quadrivalent vaccine than the bivalent vaccine; however, the major AE for the latter 
vaccine is also in the injection-related local pain (78%). 
Both HPV vaccines are classified as Pregnancy Category B by the FDA. Therefore, 
the vaccine is not recommended for pregnant women, because there are not enough 
data to ensure safety to the fetus. Studies have also demonstrated efficacy and safety 
of the vaccine in heterosexual and homosexual men. This is important as HPV also 
causes disease in men. 
A  clinical  trial  is  a  prospective  biomedical  or  health  related  research  study  of  
human  subjects  designed  to  test  new  methods  of  screening,  prevention, 
diagnosis,  or treatment  of a  disease.  These studies are conducted by physicians and 
other health professionals in a controlled environment to help determine the safety 
and efficacy of biological products, devices, drugs, medical treatments, procedures, or 
therapies to improve health. Clinical trials are conducted in phases that help answer 
different scientific questions. 
 
Phase I trials 
Test  a  new  drug  or  treatment  for  the  first  time  to  evaluate  safety  and  identify  
side  effects  in  a  small group of people. 
 
Phase II trials 
Study an experimental drug or treatment to determine its effectiveness and further 
evaluate safety in a large group of people. 
 
Phase III  trials 
Confirm  the  drug  or  treatment  effectiveness,  monitor  side  effects,  compare  it  to  
commonly  used treatments,  and  collect  information  that  will  allow  the  drug  or  
treatment  to  be  used  safely  in  larger  groups  of people. 
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Phase IV trials 
Are done after the drug or treatment has been marketed to gather information on the 
drug's effect in various populations and any side effects associated with long term use. 
 
Late 90s, an international group of scientists, trialists, methodologists and journal 
editors developed and published a checklist of essential items that they proposed to be 
included in reports, accompanied by a diagram for documenting the flow of 
participants through a trial, known as the Consolidated Standards of Reporting Trials 
(CONSORT) statement. The statement has been translated into several languages and 
is accessible via internet (http://www.consort-statement.org) in order to enhance the 
public awareness. Its use is recommended by the International Committee of Medical 
Journal Editors, the Council of Editors, and the World Association of Medical 
Editors; to date, more than 300 biomedical journals, have adopted. Since the initial 
issuing, the original CONSORT statement was revised twice and updated to a 25 
items checklist and a four-stage flow diagram, in order to facilitate critical appraisal 
and interpretation by providing guidance to authors about how to improve the 
reporting of their trials. In addition, extensions of the CONSORT Statement have 
been developed for other types of study designs, interventions and data. 
The clinical study is very important because the doctors are based in these studies and 
help us improve the biomedical research. 
Also it is reliable, while promoting medical Science. 
Methods 
Study identification & selection 
 
Studies meeting the following criteria were included: several trials were blind, 
double-blind randomized clinical trials evaluating safety and adverse effects of human 
papillomavirus (HPV) vaccines  studied subjects were older than nine years old, study 
participants with high risk of contracting, such as female sex workers and women who 
were sexual partners of HIV-infected men, and pregnant women. 
 
 
Search and selection of literature 
The studies were identified by only one database (PubMed Database 136 Papers) 
following medical subject heading terms and/or text words: (vaccines OR 
vaccination) AND (randomized controlled trial) OR (controlled clinical trial) OR 
(randomized controlled trials) OR (random location) OR (double blind method) OR 
(single blind method) OR (clinical trial) AND (Human papillomavirus) OR (HPV) 
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OR (papillomavirus) OR (papillomavirus*). Reference lists of the identified 
publications for additional pertinent studies were reviewed. Language English were 
imposed. 
 
Consort statement 
The CONSORT began in 1993, 30 experts comprised of medical journal editors, 
clinical trialists, epidemiologists, and methodologists met in Ottawa, Canada with the 
aim of developing a new scale to assess the quality of randomized controlled trial 
(RCT) reports. However, during preliminary discussions, participants felt that many 
of the suggested scale items were irrelevant because they were not regularly reported 
by authors. In fact, there was accumulating evidence that the quality of reports of 
RCTs was less than optimal. Therefore, unanimous agreement steered the remainder 
of the workshop to focus on ways to improve the reporting of RCTs. 
Participants nominated items to be included in the checklist for which there was 
evidence, whenever possible, that not adequately reporting this information could lead 
to biased estimates of the benefits of the intervention under investigation. One 
outcome of the meeting was the Standardized Reporting of Trials (SORT) statement. 
This statement consisted of a 32-item checklist and flow diagram in which 
investigators were encouraged to report on the various aspects of how RCTs were 
conducted. Concurrently, and independently, another group of experts, the Asilomar 
Working Group on Recommendations for Reporting of Clinical Trials in the 
Biomedical Literature, convened in Asilomar (California), USA, were working on a 
similar mandate. This group also published a proposal which included a checklist of 
recommended items for authors to consider when reporting RCTs. 
At the suggestion of Drummond Rennie, Deputy Editor of JAMA, representatives 
from both groups met in 1996, in Chicago, USA. The remit of this group was to 
merge the best of the SORT and Asilomar proposals into a single, coherent evidence-
based recommendation. It was felt that a single recommendation would have a better 
likelihood of appealing to journals and thus improve dissemination. The meeting 
resulted in the Consolidated Standards of Reporting Trials (CONSORT) Statement, 
which was first published in 1996.Further meetings of the Group in 1999 and 2000 
led to the publication of the revised CONSORT statement 2001. Following a meeting 
in January 2007, a further revision was developed and the CONSORT 2010 statement 
was published on March 24, 2010. Since the revision in 2001, the evidence base to 
inform CONSORT has grown considerably; empirical data had highlighted new 
concerns regarding the reporting of randomized controlled trials, such as selective 
outcome reporting. 
Therefore, a CONSORT Group meeting was convened. Thirty-one members of the 
CONSORT group met in Montebello, Canada in January 2007 to update the 2001 
CONSORT Statement. In addition to the accumulating evidence relating to existing 
checklist items, several new issues had come to prominence since 2001. Some 
participants were given primary responsibility for aggregating and synthesizing the 
relevant evidence on a particular checklist item of interest. Based on that evidence, 
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the group deliberated the value of each item. As in prior CONSORT versions, only 
those items deemed fundamental to reporting an RCT were kept. Moreover, an item 
may be fundamental to a trial but not included, such as approval by an institutional 
ethical review board, because funding bodies strictly enforce ethical review and 
medical journals usually address reporting ethical review in their instructions for 
authors. Other items may seem desirable, such as on-site monitoring, but a lack of 
empirical evidence or any consensus on their value cautions against inclusion at this 
point. The checklist thus addresses the minimum criteria. 
After the meeting, the CONSORT Executive convened teleconferences and in-person 
meetings to revise the checklist. After seven major iterations, a revised checklist was 
distributed to the larger group for feedback. With that feedback, the Executive met 
twice in person to consider all the comments and to produce a penultimate version. 
That served as the basis for writing the first draft of this paper, which was then 
distributed to the group for feedback. After consideration of their comments, the 
Executive finalized the statement. (The CONSORT Executive then drafted an updated 
explanation and elaboration (E&E) manuscript, with assistance from other members 
of the larger group. The substance of the 2007 CONSORT meeting provided the 
material for the update. The updated E&E was distributed to the entire group for 
additions, deletions, and changes. That final iterative process converged to the 
CONSORT 2010 E&E. On March 24, 2010, eight journals simultaneously published 
the CONSORT 2010 Statement, and two journals published the CONSORT 2010 
E&E.A summary of the specific changes to the CONSORT checklist was included in 
the CONSORT Statement. )The modified questionnaire separates the reporting of the 
recruitment from the follow up as well as the reporting of outcomes from the 
reporting of precision of their estimated effect. All items were investigated in terms of 
whether they were reported or not. In case of inadequate reporting or complete failure 
to report an item, those CONSORT checklist items were considered as negative 
responses. 
Data abstraction 
Given that all Randomized Controlled Trials qualified for this analysis were reported 
after 2006, the CONSORT version 2010 was used to define two reporting periods 
give .The selected manuscripts were grouped in two publication periods; The pre -
CONSORT version 2010 (2006-2009) - and post-CONSORT version 2010 (2010-
2015).The compliance to the CONSORT statement was assessed with reference to 
complete response and objective response rate. 
The two publication periods pre -CONSORT version 2010 (2006-2009) - and post-
CONSORT version 2010 (2010-2015) were compared by estimating the odds ratio 
(OR), with the respective 95% confidence interval, of reporting an item at one period 
relative to the other. Association between reporting of an item from CONSORT 
checklist and publication period was tested using the Fisher' exact test. Statistical 
significance was considered at the two-sided 0.05 level. 
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Results 
Eligible studies 
Detailed results of the literature research are presented in Figure 1.  
 
The research strategy identified 5720 potentially eligible studies by searching Medline 
(through PubMed, n = 136). Thereafter, these articles were retrieved and screened for 
eligibility. Overall, a total of 136 unique articles remained for analysis having 
complete full-text evaluation. The inter-rater agreement level between the reviewers 
in article evaluation for eligibility and in extracting the data was both relatively high. 
 
Study characteristics 
The 136 eligible articles were published during the period 2006-2015. Thirty 
manuscripts were published during the pre CONSORT version 2010 period (2006-
2009) while one hundred six were published in the post CONSORT version 2010 
period (2010-2015). 
 
Main results 
Items were reported in almost all studies were the eligibility criteria for participants 
(100%), precise details of the interventions in each group (100%). 
Overall, the reporting was improved across all items after CONSORT statement's 
implementation (Figure 2). In addition, the reporting of allocation concealment and 
implementation of randomization was poor in the majority of the reports. 
The comparison of the two periods pre -CONSORT version 2010 (2006-2009) - and 
post-CONSORT version 2010 (2010-2015) revealed a significant improvement (p < 
0.05) because the 106 papers at post -CONSORT version 2010 (2010-2015) had 
better results and more reliable from the 30 papers of pre -CONSORT version 2010 
(2006-2009). This is being because the new version is much more valid the results as 
seen in Figure 2 the two graphs of explains the difference of the method which I used. 
These items were endpoints, sample size, statistical methods, participant flow, patient 
recruitment periods, intention-to-treat analysis, estimation of effects, ancillary 
analyses, adverse events and overall evidence, which are much more likely to be 
reported in the pre -CONSORT version 2010 (2006-2009) - and post-CONSORT 
version 2010 (2010-2015),(Table 2). The median CONSHORT checklist score was 
(10,7)in 136 Papers. The score was higher in post-CONSORT reporting period 
version 2010 (2010-2015) in 106 papers10,86) than 30 papers in pre -CONSORT 
version 2010 (2006-2009) (10,70).  
Overall, the reporting was improved across all items after CONSORT statement's 
implementation (Figure 2). 
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Discussion 
This study is very important because it was the first time that I used this method pre -
CONSORT version 2010 (2006-2009) - and post-CONSORT version 2010 (2010-
2015) periods. This was a difficult method and the Research was not sufficient. The 
studies were identified by only one database (PubMed Database 136 Papers) 
following medical subject heading terms and/or text words. Studies meeting the 
following criteria were included: several trials were blind, double-blind randomized 
clinical trials evaluating safety and adverse effects of human papillomavirus (HPV) 
vaccines  studied subjects were older than nine years old, study participants with high 
risk of contracting, such as female sex workers and women who were sexual partners 
of HIV-infected men, and pregnant women. The comparison of the two periods pre -
CONSORT version 2010 (2006-2009) - and post-CONSORT version 2010 (2010-
2015) revealed a significant improvement (p < 0.05) because the 106 papers at post -
CONSORT version 2010 (2010-2015) had better results and more reliable from the 30 
papers of pre -CONSORT version 2010 (2006-2009).Physicians are based on the 
results of RCTs. It is important the reporting of these results to be completed and 
accurated. Uptoday the quality of RCTs in this disease have never been evaluated. 
 
Conclusion 
The present study investigated the quality and transparency of reporting of 
randomized controlled trials of Human Papilloma Virus (HPV) vaccines in cervical 
cancer prevention. The differences between pre -CONSORT version 2010 (2006-
2009) - and post-CONSORT version 2010 (2010-2015) periods reporting periods as 
well as between high and low quality studies were explored. 
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 to 3.2415) 
P = 0.5227 
7. Sample size 0,044(6)         0,30 (1)          0,43(5)        0,48 (4) 1.4151(0.1592
 to 12.5811) 
P = 0.7555 
8. Method of randomization (sequence generation) 0,71(97)       6,13(20)      6,72 (77)        6,95(57) 1.0896(0.5761
 to 2.0611) 
P = 0.7918 
9. Allocationconcealment 0,007(1)          0 (0)         0,08 (1)        0,12 (1) 0.8592(0.0341
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P = 0.9265 
10. Implementation of randomization 0,70(96)     6,13 (20)        6,63(76)         6,83(56) 1.0755(0.5683
 to 2.0353) 
P = 0.8231 
11. Blinding (masking) 0,30(42)        3,98(13)       2,53(29)         1,95(16) 0.6313(0.2924
 to 1.3630) 
P = 0.2415 
12. Statisticalmethods 0,44(60)         0,30(1)       5,15(59)          7,08(58) 16.6981(2.220
3 to 125.5833) 
P = 0.0062 
RESULTS 
13. Participant flow 0,80(110)       7,66(25)     7,42 (85)        7,32  (60) 0.9623(0.5267
 to 1.7580) 
P = 0.9004 
14. Periods: a. Recruitment 0,044(6)      0,61 (2)       0,34(4)          0,24 (2) 0.5660(0.0988 P = 0.5227 
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 to 3.2415) 
b. Follow-up 0,015(2)        0 (0)     0,17  (2)           0,24 (2) 1.4319(0.0669
 to 30.6307) 
P = 0.8183 
15. Baseline data 0,98(134)        9,2 (30)      9,08(104)        9,03(74) 0.9811(0.5527
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P = 0.9481 
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P = 0.9325 
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P = 0.8225 
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P = 0.6324 
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 to 14.6584) 
P = 0.6302 
DISCUSSION 
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P = 0.5227 
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 to 2.0286) 
P = 0.7383 
22. Overallevidence 0,29(40)        3,37(11)        2,53(29)          2,19 (18) 0.7461(0.3340
 to 1.6668) 
P = 0.4752 
*CONSORT= Consolidated Standards of Reporting Trials 
† The percentage of articles reporting the CONSORT item 
¥ Odds ratio of reporting an item at pre -CONSORT version 2010 (2006-2009) - and 
post-CONSORT version 2010 (2010-1015) periods. 
‡ P-Values from Fisher's exact test for testing the association between reporting an 
item and publication period. 
 
 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
26/03/2018 13:05:15 EEST - 137.108.70.6
27 
 
Figure 2: Comparison between pre Consort version 2010 (2006-
2009) and post Consort version 2010 (2010-2015) periods. 
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Figure 3: Summary Table of all the results. 
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Van Damme 
P,2014  Vaccine. 
2014 1 1 1 1 0 0 0 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 1 0 
Patel A, 2014  Vaccine. 
2014 1 0 0 0 1 0 0 1 0 1 0 1 1 0 0 1 1 1 1 0 0 0 1 1 
Lin CJ, 2014  Vaccine. 
2014 1 0 1 1 0 0 0 1 0 1 0 1 1 0 0 1 1 1 1 0 0 0 1 0 
Brown J, 2014  Vaccine. 
2014 0 1 1 1 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 1 0 
Krajden M, 2014  Vaccine. 
2014 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 1 0 
Giuliano AR, 
2015  
J Acquir 
Immune 
Defic Syndr.  
2015 0 1 1 1 0 0 0 1 0 1 0 1 1 0 0 1 1 1 1 0 0 0 1 0 
Joura EA,  2015  
N Engl J 
Med  
2015 1 1 1 1 0 1 0 1 0 1 1 1 0 0 0 1 1 1 1 0 0 0 0 1 
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